ANI Pharmaceuticals (ANIP) vs BioCryst Pharmaceuticals (BCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioCryst Pharmaceuticals (BCRX) has outperformed ANI Pharmaceuticals (ANIP) over the past year, gaining 20.9% versus a loss of 21.5%. Over five years, ANIP leads with a +86.6% price change compared with -44.5% for BCRX. BioCryst Pharmaceuticals is the larger company by market cap ($2.13 billion vs $1.66 billion), about 1.3 times the size.
On valuation, ANI Pharmaceuticals trades at a lower forward P/E (7.1x vs 8.9x for BioCryst Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIP | BCRX |
|---|---|---|
| Share price | $72.12 | $8.33 |
| Market cap | $1.66B | $2.13B |
| 1-day change | +0.26% | -0.89% |
| YTD return | -8.88% | +7.69% |
| 1-year return | -21.54% | +20.86% |
| 5-year return | +86.64% | -44.48% |
| P/E ratio (TTM) | 15.61 | — |
| Forward P/E | 7.09 | 8.86 |
| EPS (TTM) | $4.62 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $97.00 | $11.22 |
| 52-week low | $69.58 | $6.00 |
| Distance from 52-week high | -25.65% | -25.80% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +46.68% | +149.01% |
| Average volume | 372.56K | 4.11M |
| Shares outstanding | 22.96M | 255.54M |
| Employees | 970 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCRX has outperformed ANIP by 42.4 percentage points over the past year.
About ANI Pharmaceuticals
ANIP stock →ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
ANIP vs BCRX FAQ
Which is bigger, ANI Pharmaceuticals or BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals (BCRX) is larger, with a market capitalization of $2.13B compared with $1.66B for ANI Pharmaceuticals (ANIP).
Which stock has performed better over the past year, ANIP or BCRX?
BCRX returned +20.86% over the past 12 months, compared with -21.54% for ANIP (price return, excluding dividends). Past performance does not predict future results.
Are ANI Pharmaceuticals and BioCryst Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for ANI Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for BioCryst Pharmaceuticals.